Anti-TP53 R175H TCR T-cell therapy(Affini-T Therapeutics)

N/A

Report date: 2024/05/11 18:35:13

Base Information

Drug NameAnti-TP53 R175H TCR T-cell therapy(Affini-T Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionTumor protein p53 modulators
TargetsTumor protein p53
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffini-T Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAffini-T Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A